SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Pediatric Blood and Cancer Année : 2019

SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor

Résumé

To investigate the antitumor activity of a four-drug metronomic chemotherapy (MC) regimen in relapsed/progressing pediatric extracranial solid tumors (EST). The primary objective was clinical benefit (complete response /partial response/stable disease [SD]) after two cycles of therapy (four months).
Fichier non déposé

Dates et versions

hal-02528441 , version 1 (01-04-2020)

Identifiants

Citer

Marie-Amélie Heng-Maillard, Arnauld Verschuur, Audrey Aschero, Alexia Dabadie, Elisabeth Jouve, et al.. SFCE METRO‐01 four‐drug metronomic regimen phase II trial for pediatric extracranial tumor. Pediatric Blood and Cancer, 2019, 66 (7), pp.e27693. ⟨10.1002/pbc.27693⟩. ⟨hal-02528441⟩
31 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More